OncoMatch/Clinical Trials/NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Is NCT06312137 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for non small cell lung cancer.
Treatment: Sacituzumab tirumotecan · Pembrolizumab · Cisplatin · Pemetrexed · Gemcitabine · Carboplatin · Paclitaxel · Rescue medication — This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Required: TACSTD2 any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage II, IIIA, IIIB (WITH NODAL INVOLVEMENT [N2])
Prior therapy
Cannot have received: neoadjuvant therapy
Has received prior neoadjuvant therapy for their current NSCLC diagnosis
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
Cannot have received: radiotherapy
Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060) · Little Rock, Arkansas
- Highlands Oncology Group-Research Department ( Site 0062) · Springdale, Arkansas
- Beverly Hills Cancer Center ( Site 0070) · Beverly Hills, California
- The Angeles Clinic and Research Institute ( Site 0040) · Los Angeles, California
- The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079) · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06312137 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB (WITH NODAL INVOLVEMENT [N2]) is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify